Drug intelligence / Profile preview

BGB-58067 + BG-89894

Development stage: Unknown
Lead developer: BeiGene
Modality: Small Molecules
Administration: Oral

Overview

BGB-58067 + BG-89894 is an investigational combination therapy currently in Phase 1 trials for advanced solid tumors, including those with methylthioadenosine phosphorylase (MTAP) deficiency. BGB-58067 is an MTA-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor, targeting PRMT5, a protein implicated in cancer cell growth and poor outcomes when overactive. BG-89894 is a methionine adenosyltransferase 2A (MAT2A) inhibitor. The combination is specifically designed to exploit vulnerabilities in MTAP-deficient tumors by simultaneously inhibiting PRMT5 and MAT2A, both crucial for methylation-dependent tumor cell survival[1][2][3][6][7].

Targets

PRMT5 (Protein arginine N-methyltransferase 5)MAT2A (Methionine adenosyltransferase 2A)

Beyond the preview

Go deeper on BGB-58067 + BG-89894.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGB-58067 + BG-89894.

Explore the full profile